Skip to content
Screener

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Aardvark Therapeutics, Inc. logo
Aardvark Therapeutics, Inc.AARD
$0
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1K0.0%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
200M0.0%
TG Therapeutics logo
TG TherapeuticsTGTX
$160K+0.6%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
220M0.0%

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.62B+27.5%
Enterprise value$7.67B+28.8%
P/S35.1×-3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030549
Line itemMarch 31,2026December 31,2025
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 115,000 and 132,500 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $115,000 and $132,500 as of March 31, 2026, and December 31, 2025, respectively.114,710130,957
Stockholders’ equity:
Preferred stock, $0.001 par value: 9,850,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.001 par value: 120,000,000 shares authorized; 68,445,084 and 67,205,321 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively6967
Additional paid-in capital1,529,9091,491,675
Accumulated other comprehensive income (loss)444(796)
Accumulated deficit(1,407,516)(1,351,877)
Total stockholders’ equity122,906139,069

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s common stock?
Rhythm Pharmaceuticals, Inc. (RYTM) reported common stock of 120M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s common stock changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s common stock increased by 193448.4% year-over-year, from 62K to 120M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s common stock?
Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s common stock has grown at a 386.6% compound annual growth rate (CAGR), from 44K to 120M.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Rhythm Pharmaceuticals, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude